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StressCeramide is an important bioactive lipid, intimately involved in many cellular functions, including the
regulation of cell death, and in cancer and chemotherapy. Ceramide is synthesized de novo from sphinganine
and acyl CoA via a family of 6 ceramide synthase enzymes, each having a unique preference for different fatty
acyl CoA substrates and a unique tissue distribution. However, little is known regarding the regulation of
these important enzymes. In this study we focus on ceramide synthase 1 (CerS1) which is the most
structurally and functionally distinct of the enzymes, and describe a regulatory mechanism that speciﬁcally
controls the level of CerS1 via ubiquitination and proteasome dependent protein turnover. We show that
both endogenous and ectopically expressed CerS1 have rapid basal turnover and that diverse stresses
including chemotherapeutic drugs, UV light and DTT can induce CerS1 turnover. The turnover requires CerS1
activity and is regulated by the opposing actions of p38 MAP kinase and protein kinase C (PKC). p38 MAP
kinase is a positive regulator of turnover, while PKC is a negative regulator of turnover. CerS1 is
phosphorylated in vivo and activation of PKC increases the phosphorylation of the protein. This study reveals
a novel and highly speciﬁc mechanism by which CerS1 protein levels are regulated and which directly
impacts ceramide homeostasis.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionCeramide is a major bioactive lipid in eukaryotic cells. In addition
to its structural role as a membrane component [1], it is involved in a
variety of cellular functions including the regulation of cell growth,
differentiation and viability [2–4]. Ceramide homeostasis in turn is
dependent on the de novo synthesis of ceramide from sphinganine
and acyl CoA, which is catalyzed by a family of 6 ceramide synthases
[5,6]. These enzymes, named CerS1–6, are each the product of a
different gene and preferentially use different fatty acyl CoA
substrates containing fatty acid chains of different length, thereby
producing ceramides with different acyl chains [7–11]. Thus, the
regulation of these enzymes is of central importance to cell function.
Despite this rapid increase in our understanding of the enzymes
and pathways involved with regulating ceramide homeostasis, we
know relatively little about the distinct roles of each of these
pathways in normal cell physiology and in pathology. Several studies
have reported differential tissue expression patterns of the CerS genes
[10–13] and it has been reported that certain ceramides have different
roles in cancer and chemotherapy [14–16].We previously showed that+1 573 882 0123.
der).
Moores Cancer Center, La Jolla,
ll rights reserved.ectopic expression of the CerS1, CerS4 or CerS5 genes in human
embryonic kidney cells had unique effects on controlling the
sensitivity of the cells to different drugs used in cancer chemotherapy
[17]. Thus, while CerS1 sensitized cells to a wide range of drugs
including cisplatin, carboplatin, doxorubicin and vincristine, CerS5
only sensitized cells to doxorubicin and vincristine, and CerS4 did not
affect sensitivity to any of the tested drugs. Paralleling these ﬁndings,
it was shown that the speciﬁc effect of CerS1 was mediated through
the activation of the MAP kinase p38 [17]. In other studies it was
shown that the level of C18 ceramide is linked to head and neck cancer
[18,19], and CerS1 increased sensitivity to imatinib in cultured chronic
myeloid leukemia cells [20].
Underlying our lack of understanding of the speciﬁc roles of the
CerS enzymes is our lack of understanding of the levels of regulation
of the individual enzymes. The differential tissue distribution
suggests that there is a basic level of transcriptional control, but
nothing is known about possible regulation by post-translational
mechanisms, or about how drugs and other forms of stress affect
these enzymes. In this report we demonstrate that CerS1 is a protein
with a short half-life, and is turned over by ubiquitination and rapid
proteasomal degradation. A wide variety of cellular stresses includ-
ing drugs used in cancer chemotherapy, cause increased turnover of
CerS1. Furthermore, we demonstrate that CerS1 turnover is
regulated by the opposing functions of p38 MAP kinase and protein
kinase C (PKC).
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2.1. Materials
Cell culture reagents and Lipofectamine 2000 were from Invitro-
gen Corp., Carlsbad, CA. Fetal bovine serum (FBS) was from Atlanta
Biologicals, Lawrenceville, GA. Restriction enzymes were from
Promega Corp., Madison, WI. Monoclonal mouse anti-FLAG M2
antibody, polyclonal rabbit anti-FLAG antibody, cisplatin, doxorubicin,
dithiothreitol (DTT), epoxomicin and lactacystin were from Sigma-
Aldrich, St. Louis, MO. Protein A agarose beads were from Gibco, Basel,
Switzerland. MG132 was from Calbiochem, San Diego, CA. 12-O-
tetradecanoyl-phorbol-13 acetate (TPA) and anti-ubiquitin (P4D1)
antibodies were from Cell Signaling, Danvers, MA. SB203580was from
BIOMOL, Plymouth Meeting, PA, and bis-indolylmaleimide (BIM) was
from LC Laboratories, Woburn, MA. Goat anti-mouse and goat anti-
rabbit horseradish peroxidase conjugated secondary antibody and
chemiluminescent detection kits were from Pierce Biotechnology,
Rockford, IL. Optitran BA-S 85 nitrocellulose membrane was from
Whatman Schleicher and Schuell, Dassel, Germany.
2.2. Cell culture and transfection
Human embryonic kidney (HEK 293) cells were cultured in
Dulbecco's modiﬁed Eagle's medium (MEM) supplemented with
10% fetal bovine serum, 2 mM L-glutamine, non-essential amino acids,
100 IU/ml penicillin and 100 μg/ml streptomycin in a 5% CO2
incubator at 37 °C. Stable cell lines were generated by transfecting
cells at 70–80% conﬂuence in 6 well plates with 4 μg puriﬁed plasmid
DNA using Lipofectamine 2000 according to manufacturer's instruc-
tions. After 48 h the cells were transferred to a 75 cm2 culture ﬂask
andwere selected in the presence of G418 sulfate, gradually increasing
from 100 to 500 μg/ml [17]. G418 resistant cell lines were assayed for
CerS1 expression by immunoblotting using monoclonal mouse anti-
FLAG antibody, directed against the FLAG epitope. The cell lines were
stored frozen in FBS containing 10% DMSO under liquid nitrogen. The
human glioblastoma cell line U373 and the human lung cancer cell
line A549 were used to establish the regulation of endogenous CerS1
protein.
2.3. Constructs
N-terminal 3xFLAG-tagged mouse CerS1 or CerS5 fusion proteins
were generated by cloning the CerS1 or CerS5 gene into the
mammalian expression vector pCMV-3tag-1A (Stratagene) with
kanamycin selection. A mutant FLAG-CerS1 in which histidines 182
and 183 were replaced with alanines (H182A, H183A) was obtained
by amplifying two separate fragments: a 5′ fragment of the gene
using forward primer (a) 5′-aaggatccatggctgctgccgcggc and reverse
primer (b) 5′-gaggagcagggtgaccacCGCGGCcaccagcatgaccaccg-3′, and
a 3′ fragment of the gene, using forward primer (c) 5′-cggtggtca-
tgctggtgGCCGCGgtggtcaccctgctcctc-3′ and reverse primer (d) 5′-aaa-
gaattcttatcagctagcgtaatctggaacatcgtatgggtagaagagcttgtccttcacc
(mutation sites are in uppercase letters). The two fragmentswere then
used as templates to amplify the full length mutated gene, using
primers (a) and (d). The resultant PCR productwas cloned as a BamHI–
EcoRI fragment. The expression, enzyme activity and endoplasmic
reticulum localization of the N-terminally tagged proteins were the
same as previously reported [17].
2.4. Drug/stress treatment
Most experiments were performed with stable cell lines to
minimize differences in expression levels between experiments.
HEK 293 or HeLa cells expressing the FLAG-CerS1 or FLAG-CerS5
protein, U373 or A549 cells, at 90% conﬂuence, were treated with theindicated amounts of drugs for the indicated times. Cisplatin and
doxorubicin were prepared in Pt-buffer (3 mM NaCl/1 mM Na-PO4,
pH 6.4), and DTT in water. Solvent alone was added to control
untreated wells. For UV treatment, cells were exposed to UV-B for the
indicated doses followed by 6 h incubation, prior to harvesting. UV
ﬂuencewasmeasured using a Black Raymeter. The output of the lamp
was determined to be 1.6 J/s/m2, and the doses in the ﬁgures are
indicated as J/m2. In the case of drug (inhibitor/activator) co-
treatment, cells were pre-treated with indicated amounts of the
second drug for 1 h prior to the application of stress. The stresses are
used at the lowest dose for which it is possible to see a cellular
response in a reasonable amount of time and which is consistent with
many published reports (see [21–23]. These cytotoxic agents all
function in a dose- and time-dependent manner.
2.5. Inhibitors and activators
Inhibitors and activators were used at the following concentra-
tions: SB203580, 2.5 μM; BIM, 2.5 μM; TPA, 100 nM; MG132, 20 μM;
epoxomicin, 1 μM; and lactacystin, 10 μM. Control samples received an
equivalent volume of the solvent.
2.6. Immunoblotting and immunoprecipitation
For immunoblotting, following drug/stress treatment the cells
were quickly rinsed in ice-cold PBS and lysed by adding HEPES lysis
buffer (20 mM HEPES buffer, pH 7.4, 25 mM KCl, 250 mM sucrose,
10 mM N-ethyl maleimide (NEM), 1% protease inhibitor cocktail
(2.5 mM PMSF, 0.01 μg/ml pepstatin A, 0.001 μg/ml leupeptin in
methanol) containing 1% digitonin directly to the dish. The lysates
were scraped from the plates, collected in 1.5ml tubes and centrifuged
at 12,000 rpm in a Sorvall desktop centrifuge for 1 min to remove
insoluble material. Total protein in the supernatant was quantiﬁed
using the Pierce BCA protein assay reagent according to manufac-
turer's instructions. Protein concentrations between plates within an
experiment were very close and varied by less that 5%. Equal amounts
of protein were brought to the same volume and mixed with an equal
volume of 2X urea sample buffer (50 mM Tris HCl pH 6.8, 1.6% SDS, 7%
glycerol, 8 M urea, 4% β-mercaptoethanol, 0.016% bromophenol blue).
Samples were separated by SDS-PAGE on 15% gels and transferred
onto nitrocellulose membranes by standard techniques. CerS proteins
were detected with primary antibody (see below) in 0.5% casein
blocking buffer, and HRP conjugated secondary antibody, and blots
were developed with a chemiluminescent detection kit. The blots
were scanned at high resolution using an Epson Expression 1680
scanner. Ectopically expressed Flag-CerS1 or FLAG-CerS5was detected
with anti-FLAG mAb. Ubiquitinated CerS1 was detected with mouse
anti-ubiquitin antibody (P4D1). Endogenous CerS1 was detected with
anti-CerS1 rabbit antibody that was made against a synthetic peptide,
encompassing amino acids 319–337 of the human CerS1 (DLREYD-
TAEAQSLKPSKAE), conjugated to KLH. Antibodies were obtained after
an initial course of three injections, and subsequent boosts, and were
subjected to ammonium sulfate enrichment and puriﬁcation (see [24]
for general methods for producing anti-peptide antibodies). The
antibodies were tested against the cognate peptide in ELISA assays,
and by immunoblotting lysates of HEK 293 cells expressing the
recombinant CerS1 protein, and were speciﬁcally reactive in both
cases. For loading control, blots were stripped in stripping buffer
(62.5 mM Tris HCl pH 7.0, 2% SDS, 0.78% β-mercaptoethanol) at 60 °C
for 1 h and probed with mouse monoclonal anti-β tubulin antibody.
For immunoprecipitation of reduced and denatured protein,
3xFLAG-CerS1 overexpressing HEK293 cells, treated or untreated
with either 50 μM cisplatin or 2.5 μM doxorubicin, in the presence or
absence of pre-treatment with 20 μM MG132, were lysed in a buffer
containing 10 mM Tris (pH 8.0), 150 mM NaCl, 2% SDS and 10 mM
NEM. The lysates were sonicated (20 pulses) and centrifuged at
Fig. 1. Cytotoxic stresses result in down-regulation of CerS1 in a time and concentration dependent manner. Western blot analysis of CerS protein levels after stress stimuli.
Ectopically expressed FLAG-CerS1 or FLAG-CerS5 was detected with anti-FLAG monoclonal antibody (mAb), and endogenous CerS1 was detected with rabbit anti-CerS1 antibody.
The blots were stripped and probed with an anti-β-tubulin antibody as a loading control (bottom panels). (A) FLAG-CerS1 levels after 6 and 24 h treatments with the indicated
concentrations of cisplatin. (B) FLAG-CerS1 levels after 6 h treatment with indicated doses of doxorubicin (μM), DTT (mM) or UV-B light (J/m2). (C) FLAG-CerS5 levels after 6 h
treatment with cisplatin, doxorubicin or UV light. (D) Endogenous CerS1 in glioblastoma U373 cells after 6 h treatment with doxorubicin or UV-B light. (E) Endogenous CerS1 in A549
lung cancer cells after 6 h treatment with doxorubicin or UV-B light. (F) Direct comparison of CerS1 levels in U373 and A549 cells. Equal amounts of cell extract were separated on the
same gel and probed with anti-CerS1 antibody. The experiments were repeated 3 times with similar results. Molecular weight markers are shown.
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Fig. 2. Stress-mediated down-regulation of CerS1 is inhibited in the presence of the
proteasome inhibitors. Western blot analysis of ectopically expressed FLAG-CerS1
protein in (A) stably transfected HEK 293 cells, or (B) or transiently transfected HeLa
cells, untreated or treated for 6 h with 50 μM cisplatin, with or without 1 h pre-
treatment with 20 μM MG132 (note that these samples were run on a single gel). (C)
Western blot analysis of ectopically expressed FLAG-CerS1 protein in stably transfected
HEK 293 cells untreated or treated for 6 h with 50 μM cisplatin, with or without 1 h pre-
treatment with epoxomicin or lactacystin. (D) Western blot analysis of ectopically
expressed FLAG-CerS1 protein in stably transfected HEK 293 cells untreated or treated
for 6 h with 2.5 or 5 μM doxorubicin, with or without 1 h pre-treatment with MG132,
epoxomicin or lactacystin. Bottom panels, β-tubulin control. The experiments were
repeated 2 times with similar results.
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prepared for immunoprecipitation by dilution in 4 volumes of a buffer
containing 10 mM Tris (pH 8.0), 150 mM NaCl and 1% Triton-X-100
(PBST). DTT was added to a ﬁnal concentration of 1 mM. The lysates
were precleared with protein A agarose beads at 4 °C for 2 h, followed
by incubationwith rabbit anti-FLAG antibody overnight at 4 °C. FLAG-
CerS1-antibody complexes were pulled down by incubation with
protein A agarose beads for 2 h at 4 °C. The beads were washed once
with 0.5 M LiCl and 3× with 0.1% Tween in PBS. Proteins were eluted
from the beads by boiling for 5 min with urea sample buffer. The
eluted proteins were separated by SDS-PAGE (15% gel) and western
blotting was done as described above with mouse anti-ubiquitin P4D1
antibody. All immunoprecipitation and/or immunoblotting experi-
ments were done in their entirety multiple times (noted in each ﬁgure
legend) and similar results were obtained.
2.7. In vivo phosphorylation
HEK 293 cells stably expressing N-terminal FLAG tagged CerS1 or
vector control were cultured in 6-well plates, at exactly the same cell
density. The culture mediumwas replaced with phosphate-free DMEM
containing dialyzed FBS (Invitrogen, Carlsbad, CA) 1 h before adding
0.3 mCi [32P] orthophosphate (MP Biomedical, Irvine, CA; 285 Ci/mg)
per well. After 30min of incubationwith the labeled phosphate, 20 μM
MG132 and/or 200 nM TPA in DMSO were added to the cells and
incubated for 5 h. Three replicate wells of cells were used for each
treatment. The cells were lysed directly in the wells in HEPES lysis
buffer containing digitonin, protease inhibitor cocktail (described
above) and phosphatase inhibitors (15 mM sodium ﬂuoride, 1 mM
orthovanadate). The lysates from the 3 replicatewells were pooled, and
the lysates were spun at 13000 rpm at 4 °C for 5 min and each of the
supernatants was precleared with agarose beads. Each of the entire
cleared supernatants was immunoprecipitated with mouse anti-FLAG
mAb and protein A agarose. The beads are washed oncewith 0.5M LiCl
and3×with 0.1% Tween in PBS. Afterwashing, the immunoprecipitated
proteins were eluted with 2×urea sample buffer and the entire eluate
was separatedbySDS-PAGE (15%). Thegelwasdriedunder vacuumand
scanned in a phosphorimager to detect phosphorylated CerS1.
2.8. Ceramide synthase assay
In vitro ceramide synthase assay was performed as described
[17,25]. Brieﬂy, pellets were resuspended in 1 ml homogenization
buffer and homogenized as described above, and protein concentra-
tion was determined using the Bradford reagent. Homogenates (50–
250 μg protein in 0.25 ml ﬁnal volume) were incubated with 0.25 μCi
of [4,5-3H] sphinganine/15 μM sphinganine/20 μM defatted BSA, and
50 μM fatty acyl CoA (C16 for CerS5, and C18 for CerS1) for 20 min at
37 °C. Lipids were extracted, and the level of dihydroceramide
synthesis was analyzed by TLC, using chloroform/methanol/2 M
ammonium hydroxide (40:10:1; v/v/v) as the developing solvent and
using N-palmitoyl-sphingosine, and N-stearoyl-sphingosine as
authentic standards. Lipids were visualized using a phosphorimager
(Fuji), recovered from the TLC plates by scraping the silica directly into
scintillation vials, and quantiﬁed by liquid scintillation counting.
Speciﬁc enzyme activity is presented as pmol of dihydroceramide
synthesized per min per mg of protein.
3. Results
3.1. CerS1 protein undergoes turnover in response to a variety of stresses
CerS1 is structurally and functionally distinct from the other CerS
enzymes in terms of phylogeny, substrate speciﬁcity, tissue distribution,
and cellular function including the response to stress (see [5] and
Discussion). However, nothing is known about the regulation of thisenzyme at the biochemical level. To explore this, we followed the fate of
CerS1 in response to a variety of stress stimuli. Fig.1A shows that inHEK
293 cells stably expressing FLAG-CerS1, the level of FLAG-CerS1 protein
decreases following exposure to cisplatin in a dose- and time-
dependent manner. Moreover, this response was not unique for
cisplatin since treatment of the cells with diverse stresses such as
doxorubicin, dithiothreitol, or UV light resulted in a similar or greater
reduction in CerS1 protein level (Fig. 1B). In contrast, in HEK 293 cells
stably expressing FLAG-CerS5, the level of FLAG-CerS5 remains constant
after exposure to cisplatin, doxorubicin, or UV light (Fig.1C), and shows
no stress-induced turnover. Turnover of endogenous CerS1 was
demonstrated in the human glioblastoma cell line U373 and the
human lung cancer cell line A549. Fig. 1D shows that in the U373
glioblastoma cell line, following treatment with either doxorubicin or
UV light, the endogenous CerS1 protein level goes down as well. Fig. 1E
shows the decrease in endogenous CerS1 in human A549 lung cancer
cells following treatment with doxorubicin or UV light. This is
interesting because there aremixed reports regarding CerS1 expression
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the same gel) of equal amounts of U373 and A549 cells, and it can be
seen that these cell lines express approximately equal levels of CerS1
protein. It should be noted that CerS1 is also expressed in head and neck
carcinoma cells [18,19]. Taken together, these experiments indicate that
the level of both ectopically expressed and endogenous CerS1 protein is
reduced in response to a wide variety of stresses.
3.2. Stress-induced CerS1 protein turnover is proteasome dependent
To investigate the nature of the stress-induced degradation of
CerS1, HEK 293 cells expressing FLAG-CerS1 were treated with the
proteasomal inhibitor MG132 in the presence or absence of cisplatin
(Fig. 2A). As shown before, cisplatin induces turnover of CerS1 protein
compared to untreated cells (lanes 1 and 2). MG132 causes a buildup
of FLAG-CerS1 protein in untreated control cells (compare lanes 1 and
3), and substantially blocks the turnover of FLAG-CerS1 in cells treated
with cisplatin (compare lanes 2 and 4). Quantitation of the blot shows
that the MG132 inhibition of cisplatin-induced turnover (lane 4) is
75% of that seen with MG132 alone (lane 3). Fig. 2B presents similarFig. 3. CerS1 degradation is ubiquitination-mediated. HEK 293 cells stably transfected w
doxorubicin for 6 h, with or without pre-treatment with 20 μMMG132 for 1 h. Vector control
with non-denaturing buffer containing digitonin (Materials andmethods), and equal amount
protein A agarose beads. The immunoprecipitates were then subjected to immunoblot analys
the 39 kDa FLAG-CerS1 protein was indeed immunoprecipitated (lower panel). (B an
immunoprecipitation proteins. Following Immunoprecipitationwith anti-FLAGmAb and pro
associated proteins (see Materials and methods). The immunoprecipitates were then subject
mAb (C). The experiments were repeated 2 times with similar results. (Ub)n-CerS1 — ubiqresults when FLAG-CerS1 is transiently expressed in HeLa cells. Again
MG132 substantially blocks the cisplatin-induced turnover of FLAG-
CerS1 in HeLa cells, and shows that the effect is not cell-type speciﬁc.
In addition, two other proteasome inhibitors, epoxomicin and
lactacystin, block the cisplatin and doxorubicin induced turnover of
FLAG-CerS1 stably expressed in HEK 293 cells (Fig. 2C and D). These
results indicate that under non-stress conditions, CerS1 is turned over
by a proteasome dependent process, and that the increased turnover
due to stress is also dependent on proteasome function.
3.3. CerS1 proteasomal degradation is ubiquitin mediated
The ability of proteasome inhibitors to block CerS1 protein
turnover suggested that ubiquitination is required. HEK 293 cells
stably expressing FLAG-CerS1 were treated with cisplatin or buffer
alone. Extracts were prepared using the standard non-denaturing
buffer that is used to prepare samples for immunoblotting. The FLAG-
CerS1 was immunoprecipitated using anti-FLAG antibody, and the
immunoprecipitated proteins were separated by SDS-PAGE and
analyzed by immunoblotting with anti-ubiquitin mAb or anti-FLAGith FLAG-CerS1 (denoted FLAG-CerS1) were treated with 50 μM cisplatin or 2.5 μM
cells (V) are HEK 293 cells stably transfected with empty vector. (A) Cells were extracted
s of extracted proteinwere immunoprecipitated with anti-FLAGmAb and captured with
is, using mouse anti-ubiquitin mAb P4D1 (upper panel), or anti-FLAGmAb to show that
d C) The cells were extracted under strongly denaturing conditions to avoid co-
tein A agarose, the beads were washed in chaotropic 0.5 M LiCl to dissociate any further
ed to immunoblot blot analysis, using mouse anti-ubiquitin mAb P4D1 (B), or anti-FLAG
uitinated CerS1, IP — immunoprecipitation, WB — Western blot.
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protein accumulates in cells treated with the proteasomal inhibitor
MG132 (compare lane 2 to lane 1) and that treatment with cisplatin
increases the amount of the ubiquitinated protein (compare lanes 3
and 4 to lanes 1 and 2, respectively). Parallel immunoprecipitation
from the same extracts with anti-FLAG mAb followed by immuno-
blotting with anti-FLAG mAb showed that the 39 kDa FLAG-CerS1
protein was indeed immunoprecipitated (lower panel of Fig. 3A).
The foregoing experiment did not preclude the possibility that the
ubiquitinated proteins were associated proteins that co-immunopre-
cipitated with CerS1. To eliminate this possibility, the experiment was
re-performedwhere the cell extracts were prepared in denaturing and
reducing conditions to avoid co-immunoprecipitation of associated
proteins, and the immunoprecipitates were washed in strongly
chaotropic buffer to dissociate any further associated proteins.
Samples were prepared from both cisplatin and doxorubicin treated
cells to demonstrate the generality of the effect. The immunopreci-
pitated CerS1 protein were separated by SDS-PAGE and analyzed by
immunoblotting with anti-ubiquitin mAb (Fig. 3B). Again, the data
show clearly that either stress, cisplatin or doxorubicin, causes a
signiﬁcant increase in ubiquitinated CerS1 protein. Some slowlyFig. 4. Basal turnover of CerS1 is rapid and inhibited by the proteasome-inhibitor MG132. HEK
cycloheximide (CHX, 30 μg/ml) for the indicated time periods, in the presence or absence of 1
were treated with cycloheximide for the indicated times and endogenous CerS1 was detect
cycloheximide, with or without 50 μM cisplatin for 1 h. Addition of MG132 blocks proteaso
experiments were repeated 2 times with similar results.migrating ubiquitinated protein reacts with the anti-ubiquitin anti-
body in control cells (compare lane 2 to the vector control in lane 1).
Cells stressed with either doxorubicin (lane 5) or cisplatin (lane 6)
contain more of the slowly migrating ubiquitinated CerS1 proteins
than the untreated cells (lane 2). Treatment withMG132 results in the
accumulation of the slowly migrating ubiquitinated proteins (com-
pare lane 4 to lane 2) and treatment with either cisplatin or
doxorubicin signiﬁcantly increases the level of ubiquitinated CerS1
protein (compare lanes 3 and 7 to lane 4). Parallel, anti-FLAG
immunoprecipitations from the same extracts that were analyzed by
immunoblotting with anti-FLAG (Fig. 3C) show that the 39 kDa FLAG-
CerS protein was immunoprecipitated, and that here too, the stresses
result in a signiﬁcant increase in the slowly migrating proteins
(compare lanes 3 and 7 to lane 4). Taken together, these studies
demonstrate a basal level of CerS1 ubiquitination in untreated cells
and increased level in stressed cell.
3.4. CerS1 has a short half-life
The foregoing data suggested that CerS1 protein rapidly turns over
in response to stress, and this led us to ask about basal turnover. This293 cells, stably transfected with FLAG-CerS1 (A) or FLAG-CerS5 (B) were treated with
h pre-treatment with 20 μMproteasome-inhibitor MG132. (C) Glioblastoma U373 cells
ed. (D) HEK 293 cells stably transfected with FLAG-CerS1 were treated with 30 μg/ml
me mediated turnover. All experiments are Western analysis as described in Fig. 1. The
1224 P. Sridevi et al. / Biochimica et Biophysica Acta 1793 (2009) 1218–1227was directly tested by monitoring the level of CerS1 protein in cells
treated with cycloheximide to inhibit protein synthesis. Fig. 4A shows
that the 37 kDa FLAG-CerS1 stably expressed in HEK 293 cells rapidly
turns over with a half-life of about 20–30 min and that MG132
substantially blocks this turnover. In contrast, Fig. 4B shows that the
level of the 50 kDa FLAG-CerS5 protein stably expressed in HEK 293
cells is stable following cycloheximide treatment, indicating that it is
not being turned over. Treatment of human U373 glioblastoma cells
with cycloheximide shows that the endogenous CerS1 is also turning
over rapidly, and this turnover is blocked byMG132 (Fig. 4C). The data
in Fig. 4D show that when HEK 293 cells expressing FLAG-CerS1 are
treated with cisplatin in addition to cycloheximide, there is an
increased level of turnover than in the presence of cycloheximide or
cisplatin alone, and this is reversed by the proteasomal inhibitor
MG132. These data demonstrate a high basal level of CerS1 protein
turnover that can be increased with stress.
3.5. CerS1 enzyme activity is required for its turnover
The current study has shown that upon stress there is a loss of
CerS1 protein in the cells. Therefore, it was of interest to determine if
the catalytic activity of CerS1 is required for its stress-induced
degradation. CerS1, like all other CerS proteins, has a Lag1p motif
which has been shown to be necessary for catalytic activity, and it has
been shown that mutating the histidines at positions 182 and 183 to
alanines results in a loss of almost all enzymatic activity [9]. This
molecular genetic approach is more speciﬁc than using relatively non-
speciﬁc inhibitors of ceramide synthesis such as fumonisin or
myriocin which inhibit either all ceramide synthases or the upstream
serine palmitoyl transferase, respectively, and the change of two
amino acids is unlikely to alter the folding or membrane topology of
CerS1 as previously shown [7,26]. Thus, to test whether the activity ofFig. 5. Catalytically inactive CerS1 mutant does not undergo stress-induced degradation. (
(H182A,H183A). Equal amounts of protein extracts were assayed for in vitro activity, using 3
mutant FLAG-CerS1(H182A,H183A). HEK 293 cells stably expressing FLAG-CerS1 or FLAG-Ce
as described in Fig. 1. (C) The response of mutant FLAG-CerS1(H182A,H183A) to stress. HEK 2
indicated amounts of cisplatin for 6 h, and subjected to Western analysis. (D) Ubiquitination
fromHEK 293 cells stably expressing FLAG-CerS1 or FLAG-CerS1(H182A,H183A), treated with
a clear increase in ubiquitination after cisplatin treatment of wild-type cells that is absent in
the stabilization of the ubiquitinated CerS1 (Fig. 3)). Western blotting was done with mou
light chain; (Ub)n-CerS1-ubiquitinated CerS1. The experiment was repeated 2 times with sCerS1 is necessary for stress-induced degradation, we generated the
H182A, H183A mutant, which showed greatly reduced activity in
comparison to the parent protein (Fig. 5A). We also determined the
basal turnover rate of the catalytically inactive mutant protein in the
presence of cycloheximide (Fig. 5B). The mutant protein has a rapid
basal turnover rate similar to the wild-type (Fig. 2), which indicates
that it can turnover, and that basal turnover is not dependent on
catalytic activity. In contrast, the mutant FLAG-CerS1, which lacks
enzyme activity, shows no turnover (Fig. 5C) in response to cisplatin
even at very high concentrations while thewild-type protein is turned
over. Fig. 5D shows that ubiquitination of the inactive mutant FLAG-
CerS1 enzyme does not increase much beyond the level seen in the
absence of stress, in contrast to ubiquitination of wild-type FLAG-
CerS1 which is increased in the cisplatin-treated cells. Taken together,
these data indicate that CerS1 is mechanistically involved in
regulation of its own level in response to stress.
3.6. The p38 MAP kinase is a positive regulator of CerS1 protein turnover
We previously showed that the p38 MAP kinase was an essential
component of the signaling mechanism mediating how ceramide
controls cellular sensitivity to drugs [17,27,28]. Moreover, it has been
reported that p38 regulates the activities of ubiquitin ligases [29].
Together this suggested that the rapid turnover of CerS1 might reﬂect
the action of p38 on turnover of the protein. To this end we used the
speciﬁc p38 inhibitor SB203580 to see if the turnover of FLAG-CerS1
protein was also p38-dependent. The data in Fig. 6 show that
SB203580 has no effect itself on untreated control HEK 293 cells
expressing FLAG-CerS1 (compare lanes 4 and 1). However, SB203580
inhibits the cisplatin-induced turnover of FLAG-CerS1 (compare lanes
5 and 2). Treatment of the SB203580/cisplatin-treated cells with the
proteasomal inhibitor MG132 slightly increases the level of FLAG-A) In vitro ceramide synthase enzyme activity of FLAG-CerS1 and mutant FLAG-CerS1
H-sphinganine and C18 acyl CoA conﬁrming published results [9]. (B) Basal turnover of
rS1(H182A,H183A) were treated with cycloheximide and analyzed by Western analysis
93 cells stably expressing FLAG-CerS1 or FLAG-CerS1(H182A,H183A) were treated with
of mutant FLAG-CerS1 is not increased following stress. Equal concentrations of extracts
50 μM cisplatin for 6 h, were immunoprecipitated with mouse anti-FLAGmAb. There is
the mutant. (Note that this analysis was done in the absence of MG132 which results in
se anti-ubiquitin (P4D1) antibody. H-immunoglobulin heavy chain; L-immunoglobulin
imilar results.
Fig. 6. p38 MAP kinase is a positive regulator of CerS1 protein turnover. Western blot
showing the inhibition of cisplatin-induced CerS1 protein turnover in HEK 293 cells
stably expressing FLAG-CerS1 by the p38MAP kinase inhibitor SB203580 (compare lane
3 to lane 2). The inhibitor (2.5 μM) was added 1 h before the addition of cisplatin and
the samples were harvested 6 h later. Western blotting was as described in Fig. 1.
Addition of MG132 blocks turnover, conﬁrming the results in Fig. 2. The experiment was
repeated 2 times with similar results.
Fig. 8. In vivo phosphorylation of CerS1. HEK 293 cells stably expressing FLAG-CerS1
were metabolically labeled with [32P] orthophosphate (see Materials in Methods) in
presence or absence of the PKC activator TPA and MG132 to prevent proteasome
mediated turnover. The entire radiolabeled extracts were immunoprecipitated with
anti-FLAG mAb. The immunoprecipitated labeled FLAG-CerS1 samples were electro-
phoresed on the same gel and the radioactivity was detected using a Fuji
Phosphorimager. The experiments were repeated 2 times with similar results.
1225P. Sridevi et al. / Biochimica et Biophysica Acta 1793 (2009) 1218–1227CerS1 (compare lane 6 to lane 5) as it did in cells treated with cisplatin
alone (lane 3). Thus, p38 has a novel role in positively regulating the
level of CerS1 protein.
3.7. Protein kinase C (PKC) is a negative regulator of CerS1
protein turnover
PKC is known to be involved in regulating the turnover of other
proteins via phosphorylation [29–31], and examination of the
sequence of the CerS1 protein indicates that there are several putative
phosphorylation sites. Therefore, we looked at whether modulating
PKC activity could in turn modulate the turnover of CerS1 protein.
Fig. 7A shows that when FLAG-CerS1 expressing cells are treated
with the PKC inhibitor BIM, there is a dramatic increase in FLAG-CerS1
protein turnover (lane 2) compared to the untreated control cells
(lane 1). Treatment with MG132 blocks the BIM induced turnoverFig. 7. PKC is a negative regulator of CerS1 protein turnover. (A) HEK 293 cells stably express
causes CerS1 turnover (compare lane 2 to lane1) and increases the cisplatin-induced CerS1 t
to lane 9) and reverses the cisplatin-induced turnover of FLAG-CerS1 (lane 14). MG132 block
samples 1–8 and 9–16 were run on parallel gels, which were blotted and processed togethe
CerS1 was detected. The experiments were repeated 2 times with similar results.(lane 4). When BIM and cisplatin are added together (lane 6), there is
greater FLAG-CerS1 turnover compared to BIM or cisplatin alone
(lanes 2 or 5, respectively). MG132 reverses the effects of cisplatin
alone (lane 7) or BIM and cisplatin together (lane 8).
In contrast, when cells are treatedwith the PKC activator TPA, there
is a decrease in FLAG-CerS1 turnover (compare lane 10 to lane 9). TPA
reduced cisplatin-induced FLAG-CerS1 turnover (compare lane 14 to
lane 13). TPA and MG132 together prevent cisplatin-induced FLAG-
CerS1 turnover to a greater extent than TPA or MG132 alone (compare
lane 16 to lanes 14 and 15, respectively). In the U373 glioblastoma
cells, BIM induces turnover of endogenous CerS1 and TPA appears to
have some stabilizing effect on endogenous CerS1 (Fig. 7B). Therefore,
activation or inhibition of PKC have opposite effects on the
proteasomal mediated turnover of CerS1, and demonstrate a negative
regulatory role for PKC on CerS1 protein turnover.
These data, and the presence of putative phosphorylation sites in
CerS1, suggested that PKC acts on CerS1 by phosphorylation.We tested
this by in vivo phosphorylation of HEK cells expressing FLAG-CerS1, by
labeling cellswith [32P] orthophosphate in the presence and absence ofing FLAG-CerS1 were treated with the PKC inhibitor BIM, or the PKC activator TPA. BIM
urnover (lane 6). In contrast, TPA, inhibits the turnover of FLAG-CerS1 (compare lane 10
s the turnover of FLAG-CerS1 as shown in Fig. 2. All treatments were done together and
r. (B) Human glioblastoma U737 cells were treated with BIM and TPA and endogenous
Fig. 9. The regulation of CerS1 protein turnover. Model showing the opposing roles for
p38 MAP kinase and PKC in regulating the turnover of CerS1 in stressed and unstressed
cells. Previous work showed that stress activates p38 MAP kinase in a CerS1 dependent
manner [17]. There are multiple mechanisms by which PKC can be exerting its negative
inﬂuence on CerS1 turnover, and they are discussed in the text. UbL-ubiquitin ligase.
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anti-FLAG mAb and separated by SDS-PAGE. The data in Fig. 8 show
that there is a basal level of phosphorylation of FLAG-CerS1 (lane 1),
and TPA increases the level of phosphorylated FLAG-CerS1 (lane 2).
The proteasome-inhibitor MG132 resulted in only a minor increase
in phosphorylated FLAG-CerS1 due to the decreased protein turnover
(lane 3), while the further addition of TPA (in addition to MG132)
substantially increased the level of phosphorylated FLAG-CerS1 (lane
4) although TPA does not decrease turnover beyond the effect of
MG132 alone. This is the ﬁrst demonstration that CerS1 is phosphory-
lated. This supports the idea that TPA activation of PKC results in an
increase in phosphorylation of FLAG-CerS1, rather than simply by the
inhibition of CerS1 turnover.
4. Discussion
Six ceramide synthase enzymes are responsible for the de novo
synthesis of all the ceramide in mammalian cells [5]. Although highly
homologous, the CerS1 enzyme is structurally, catalytically, and
functionally unique compared to the other CerS enzymes. CerS1 is
phylogenetically distinct, lacks a HOX-like domain [5], preferentially
uses C18 acyl CoA as a substrate [13], is expressed (mRNA) most
abundantly in the brain and heart [10], increases sensitivity to speciﬁc
chemotherapeutic agents [17,20], and is associated with the alteration
of C18 ceramide levels in carcinomas of the head and neck [18,19].
However, nothing was known about the regulation of the CerS1
enzyme.
In this study we directly tested the idea that CerS1 is differentially
regulated post-translationally, thereby providing a sensitive and
rapid level of modulation beyond that controlled by transcription.
The data show that both endogenous and ectopically expressed
CerS1 are regulated at the level of protein turnover. We demon-
strated that 1) the basal level of CerS1 is rapidly turned over by
ubiquitination and proteasomal mediated degradation; 2) stresses
including cisplatin, doxorubicin, DTT and UV light induce ubiquitin/
proteasomal mediated CerS1 turnover; 3) CerS1 catalytic activity is
necessary for turnover, thus identifying a novel negative feedback
mechanism for CerS1 function; 4) the p38 MAP kinase, which has
been previously shown to be speciﬁcally up-regulated in cells
expressing CerS1, is also a positive regulator of the turnover of
CerS1; 5) that PKC is a negative regulator of CerS1 turnover; and 6)
that CerS1 is phosphorylated and that PKC activation increases CerS1
phosphorylation.
The stress-induced turnover of both endogenous and ectopically
expressed CerS1 appears to be very general and independent of the
type of stress. Thus, cytotoxic drugs, inducers of the unfolded protein
response and UV-light all of which operate by different mechanisms of
action, ultimately result in CerS1 protein turnover, conﬁrming the
importance of this enzyme in regulating ceramide homeostasis. It is
important to note in this context that all of these diverse cellular
stresses have been associated with eliciting an increase in reactive
oxygen species (ROS; [32], and future work should test whether ROS
are mediators of CerS1 turnover. For example, inhibitors of ROS could
be tested for their ability to abrogate stress-induced CerS1 turnover. In
this regard, it has been noted that changes in ROS appear to follow
changes in cellular ceramide levels [33].
Fig. 9 presents a model summarizing the results of this study. Both
basal and stress-induced CerS1 turnover are mediated by its
ubiquitination and proteasomal degradation. The p38 MAP kinase is
a positive regulator of CerS1 protein turnover. We have previously
shown that cisplatin or doxorubicin treatment of CerS1 expressing
cells results in a robust activation of p38 enzyme activity [17], which is
consistent with the increase in CerS1 protein turnover in stressed
cells. Moreover, the demonstration that CerS1 catalytic activity is
necessary for protein turnover in response to stress suggests the
presence of an autoregulatory feed back loop involving ubiquitinationof CerS1, but the precise molecular details will require additional
investigation.
The precise role of PKC in CerS1 turnover will require additional
experimentation. There aremultiple isoforms of PKC, which have been
shown to regulate different cellular functions. Of the 8 isoforms, 5
(α, β, γ, δ, ɛ) are inhibited by BIM. Other inhibitors with different
patterns of inhibition ultimately can be used to identify which of these
is speciﬁcally involved in regulating CerS1 turnover. Mechanistically,
PKC might be acting on CerS1 directly by speciﬁc phosphorylation, or
indirectly via an intermediary signaling protein. Indeed, CerS1 has 5
putative serine or threonine phosphorylation sites that can be
mutated to determine their role in CerS1 turnover. In vitro experi-
ments testing the ability of PKC to phosphorylate CerS1 are needed to
distinguish between these mechanisms. Nevertheless, this is the ﬁrst
demonstration that CerS1 is phosphorylated in vivo. Other studies
have shown that PKC is a negative regulator of GMFβ, an enhancer of
p38 MAP kinase [34]. In this context, inhibition of PKC could result in
the upregulation of GMFβ or another intermediate signalingmolecule,
which in turn would activate p38, subsequently causing the turnover
of CerS1. PKC has also been shown to have an effect on p38 via
ceramide generation through the activation of sphingomyelinase
[35,36], and it will be important to reconcile these studies with the
current work on CerS1 turnover. Overall, these studies demonstrate a
novel mechanism for the modulation of CerS1 enzyme levels in
response to stress.
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